Clinical Trial Update: Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing BI 1356 (linagliptin) to placebo in adults with type 2 diabetes and inadequate glycemic control has completed, with efficacy and safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Linagliptin (linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2011-06-07